POPA ReconBrian Armstrong's NewLimit Raises $435M in Series C Funding
Brian Armstrong's NewLimit Raises $435M in Series C Funding NewLimit develops medicines designed to restore youthful function in old cells through epigenetic reprogramming, using AI and genomics tools to identify candidates. Its lead program targets liver health, with the therapy intended to help livers heal faster after injury and recover from dietary and alcohol-related damage. The company was founded in 2021 by Brian Armstrong, former GV partner and bioengineer Blake Byers, and computational biologist Jacob Kimmel, who serves as CEO and President. 👉 x.com/newlimit/status/206184923715615…
The excerpt is quoted from a public Telegram channel, which owns its text.